Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 36.18

-4.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	1/23/2005 10:10:44 AM
	of 566

From BioCentury: Rigel (RIGL) fell $1.71 to $20.06 last week despite partnering with Pfizer (PFE) to develop RIGL’s preclinical Syk kinase inhibitors for allergic asthma and other respiratory diseases (see B4). Moreover, RIGL retained rights to its lead Syk kinase inhibitor, R112, which is in Phase II trials for allergic rhinitis. PFE does have a “limited option” to license the compound after RIGL completes additional Phase II trials, but EVP and COO Raul Rodriguez noted that the pharma company’s option “is soft — we don’t have to give it to them.” Rodriguez said RIGL wants to run the additional Phase IIs on its own and expects to partner the compound in the next 12 months. “We’re starting allergy trials that compare R112 with steroids,” he said. “We’re looking to show equal symptom improvement and a faster onset of action. Steroids take a couple of days to kick in. In our last Phase II, we had onset of action within 30 minutes.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next